Literature DB >> 8972009

More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT.

G J Despotis1, J H Joist, C W Hogue, A Alsoufiev, D Joiner-Maier, S A Santoro, E Spitznagel, J I Weitz, L T Goodnough.   

Abstract

This study was designed to determine whether the maintenance of higher than usual patient-specific heparin concentrations during cardiopulmonary bypass (CPB) was associated with more effective suppression of hemostasis system activation. Thirty-one patients scheduled for repeat cardiac surgery or combined procedures (i.e., coronary revascularization + valve repair/replacement) were consented and enrolled in this study. All patients received porcine heparin and protamine and were randomly assigned to monitoring of anticoagulation by either celite ACT alone (Control, n = 16) or by kaolin ACT combined with on-site measurements of whole blood heparin concentration (Intervention, n = 15). Blood specimens collected before administration of heparin, before weaning from CPB and after administration of protamine were analyzed with a battery of coagulation assays. Patients in the intervention cohort received appreciably greater heparin doses than control patients, resulting in higher anti-Xa heparin levels at the end of CPB. Fibrinopeptide A and D-dimer levels were higher in the control group before discontinuation of CPB. Percent decrease during CPB were greater in the control group for factors V and VIII, fibrinogen and antithrombin III. Percent decrease in complement 3 was greater in the control group after protamine and bleeding times measured in the Intensive Care Unit were significantly more prolonged in this group. Maintenance of higher patient-specific heparin concentrations during CPB more effectively suppresses excessive hemostatic system activation than do standard heparin doses chosen based on measurement of ACT. These findings may explain, at least in part, the significant reduction in perioperative blood loss and blood product use when higher heparin concentrations are maintained.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972009

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass.

Authors:  Satoru Ogawa; James E Richardson; Tetsuro Sakai; Masahiro Ide; Kenichi A Tanaka
Journal:  J Anesth       Date:  2011-10-19       Impact factor: 2.078

2.  Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery.

Authors:  Javier Suárez Cuenca; Pilar Gayoso Diz; Francisco Gude Sampedro; J Marcos Gómez Zincke; Helena Rey Acuña; M Manuela Fontanillo Fontanillo
Journal:  J Extra Corpor Technol       Date:  2013-12

3.  A pilot goal-directed perfusion initiative is associated with less acute kidney injury after cardiac surgery.

Authors:  J Trent Magruder; Todd C Crawford; Herbert Lynn Harness; Joshua C Grimm; Alejandro Suarez-Pierre; Chad Wierschke; Jim Biewer; Charles Hogue; Glenn R Whitman; Ashish S Shah; Viachaslau Barodka
Journal:  J Thorac Cardiovasc Surg       Date:  2016-09-19       Impact factor: 5.209

4.  The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement.

Authors:  David Machin; Philip Devine
Journal:  J Extra Corpor Technol       Date:  2005-09

5.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03

6.  [Off-pump versus on-pump coronary artery bypass surgery. Comparison of 270 case-matched elderly patients].

Authors:  Markus K H Fritz; Albrecht Wiebalck; Dirk Buchwald; Delawer Reber; Krzysztof Klak; Axel M Laczkovics
Journal:  Z Kardiol       Date:  2004-08

Review 7.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

8.  Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey.

Authors:  Melania M Bembea; Gail Annich; Peter Rycus; Gary Oldenburg; Ivor Berkowitz; Peter Pronovost
Journal:  Pediatr Crit Care Med       Date:  2013-02       Impact factor: 3.624

9.  Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements.

Authors:  Sean Garvin; Daniel C FitzGerald; George Despotis; Prem Shekar; Simon C Body
Journal:  Anesth Analg       Date:  2009-10-27       Impact factor: 5.108

10.  Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery.

Authors:  Kenichi A Tanaka; Vinod H Thourani; Willis H Williams; Peggy G Duke; Jerrold H Levy; Robert A Guyton; John D Puskas
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.